Fractyl Health (GUTS) Projected to Post Quarterly Earnings on Monday

Fractyl Health (NASDAQ:GUTS) is projected to announce its Q4 2025 results before the market opens on Monday, March 2nd. Analysts expect Fractyl Health to post earnings of ($0.19) per share for the quarter. Interested persons may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Tuesday, March 3, 2026 at 4:30 PM ET.

Fractyl Health Stock Up 1.5%

GUTS stock opened at $0.47 on Monday. The business has a fifty day simple moving average of $1.54 and a 200-day simple moving average of $1.37. Fractyl Health has a 52 week low of $0.38 and a 52 week high of $3.03. The company has a market cap of $64.18 million, a price-to-earnings ratio of -0.20 and a beta of 1.67.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the stock. Nantahala Capital Management LLC acquired a new position in Fractyl Health in the third quarter worth $19,298,000. Marshall Wace LLP lifted its position in shares of Fractyl Health by 234.9% in the 4th quarter. Marshall Wace LLP now owns 5,926,745 shares of the company’s stock worth $13,039,000 after buying an additional 4,156,969 shares during the last quarter. Alyeska Investment Group L.P. acquired a new position in shares of Fractyl Health in the 3rd quarter valued at about $8,981,000. Woodline Partners LP grew its position in shares of Fractyl Health by 821.1% during the 3rd quarter. Woodline Partners LP now owns 5,506,534 shares of the company’s stock valued at $8,755,000 after buying an additional 4,908,693 shares during the last quarter. Finally, General Catalyst Group Management LLC bought a new stake in shares of Fractyl Health during the 2nd quarter valued at about $7,912,000.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on GUTS. Canaccord Genuity Group reiterated a “buy” rating and set a $8.00 target price on shares of Fractyl Health in a report on Friday, December 19th. HC Wainwright reiterated a “buy” rating and set a $8.00 price objective on shares of Fractyl Health in a research note on Tuesday, December 2nd. Weiss Ratings reissued a “sell (d-)” rating on shares of Fractyl Health in a research report on Monday, December 29th. Finally, Morgan Stanley lowered shares of Fractyl Health from an “overweight” rating to an “equal weight” rating and reduced their target price for the company from $8.00 to $2.00 in a report on Thursday, January 29th. Three research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $5.40.

Fractyl Health Company Profile

Fractyl Health, Inc is a clinical-stage medical technology company focused on the development and commercialization of minimally invasive, endoscopic therapies for metabolic diseases. Headquartered in Lexington, Massachusetts, Fractyl is advancing treatments that target the underlying physiology of conditions such as type 2 diabetes, obesity and nonalcoholic fatty liver disease (NAFLD) by modifying the duodenal mucosa to improve metabolic control.

The company’s lead product, Revita® Duodenal Mucosal Resurfacing (Revita DMR), employs a catheter-based hydrothermal ablation technique to remodel the lining of the upper small intestine.